<DOC>
	<DOCNO>NCT02598661</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety imetelstat transfusion dependent participant low intermediate-1 risk myelodysplastic syndrome ( MDS ) relapsed/refractory erythropoiesis-stimulating agent ( ESA ) treatment .</brief_summary>
	<brief_title>Study Evaluate Imetelstat ( JNJ-63935937 ) Subjects With International Prognostic Scoring System ( IPSS ) Low Intermediate-1 Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>This Phase 2/3 , multicenter study imetelstat consist 2 part . Part 1 open‐label , single-arm design ass efficacy safety imetelstat . Up 30 participant enrol follow safety , hematologic improvement reduction transfusion requirement . Part 2 study initiate data Part 1 supportive satisfactory benefit/risk profile . Part 2 double‐blind , randomize design compare efficacy imetelstat placebo . Approximately 170 participant randomize 2:1 ratio receive either imetelstat placebo , respectively . Each part study consist 3 phase : Screening phase ( 28 day ) ; treatment phase ; post-treatment follow-up phase continue death , lose follow-up , withdrawal consent , End Study ( whichever occurs first ) . The End Study define 2 year study entry last participant anytime sponsor terminates study , whichever come first .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Man woman great equal ( &gt; = ) 18 year age Diagnosis myelodysplastic syndrome ( MDS ) accord World Health Organization ( WHO ) criteria classification confirm bone marrow aspirate biopsy within 12 week prior Study Entry . A local laboratory report diagnostic bone marrow aspirate biopsy must review approve sponsor International Prognostic Scoring System ( IPSS ) low Risk intermediate1 risk MDS Red blood cell ( RBC ) transfusion dependent , define require least 4 RBC unit transfuse 8week period 16 week prior Study Entry ; pretransfusion hemoglobin ( Hb ) less equal 9.0 gram per deciliter ( g/dL ) count towards 4 unit total Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Participant know allergy , hypersensitivity , intolerance imetelstat excipients Participant receive investigational drug use invasive investigational medical device within 30 day prior Study Entry currently enrol investigational study Prior treatment imetelstat Have receive chemotherapy , immunomodulatory immunosuppressive therapy , corticosteroid great 30 milligram per day prednisone equivalent , growth factor treatment within 28 day prior study entry Have receive treatment MDS within 4 week prior Study Entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Imetelstat</keyword>
</DOC>